...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Epizyme market cap $750 mil USd

Tada - you make a really great point on the ease of buying out of a private company compared to a public company.  I hadn't really thought about that too much, but that all makes very good sense to me that it might actually be easier to do so without being subject to shareholder and public scrutiny as much etc.  Great dialogue!

Cheers,

10BagR

Share
New Message
Please login to post a reply